Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer

Published:December 29, 2017DOI:



      The effect of germline BRCA mutations on the outcomes of patients with triple-negative breast cancer (TNBC) is not well understood.

      Materials and Methods

      The present retrospective study included women with newly diagnosed TNBC from January 1, 2004 to December 30, 2013. The demographic and tumor characteristics, genetic testing results, and outcomes were collected by a review of the patients’ medical records. The outcomes were compared between the BRCA+ and BRCA women. Kaplan-Meier curves were plotted for survival analysis, and Cox proportional hazard regression was used to determine the predictors of recurrence-free survival.


      A total of 266 TNBC patients who had undergone BRCA testing were included in the final analysis. Of the 266 patients, 72 (27.0%) tested positive for a pathogenic BRCA mutation and 194 (73.0%) tested negative. BRCA+ women were more likely to be diagnosed with breast cancer at a younger age than were the BRCA women. Mutation carriers were also more likely to undergo bilateral mastectomy and less likely to receive radiation. The 2- and 5-year overall survival in BRCA+ women was 97.1% and 83.1% and was 97.3% and 89.7% in the BRCA women, respectively. No statistically significant difference was found in overall survival between the BRCA+ and BRCA group. No statistically significant difference was noted in the rate of locoregional recurrence, distant recurrence, or recurrence-free survival between the BRCA+ and BRCA women.


      Our study has demonstrated that BRCA mutation carrier status does not affect overall survival or recurrence-free survival in patients with TNBC.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2017.
        CA Cancer J Clin. 2017; 67: 7-30
        • Viale G.
        The current state of breast cancer classification.
        Ann Oncol. 2012; 23: 207-210
        • Weigelt B.
        • Baehner F.L.
        • Reis-Filho J.S.
        The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.
        J Pathol. 2010; 220: 263-280
        • Sotiriou C.
        • Pusztai L.
        Gene-expression signatures in breast cancer.
        N Engl J Med. 2009; 360: 790-800
        • Kreike B.
        • van Kouwenhove M.
        • Horlings H.
        • et al.
        Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
        Breast Cancer Res. 2007; 9: R65
        • Foulkes W.D.
        • Smith I.E.
        • Reis-Filho J.S.
        Triple-negative breast cancer.
        N Engl J Med. 2010; 363: 1938-1948
        • Rakha E.A.
        • Reis-Filho J.S.
        • Ellis I.O.
        Basal-like breast cancer: a critical review.
        J Clin Oncol. 2008; 26: 2568-2581
        • Dent R.
        • Hanna W.M.
        • Trudeau M.
        • Rawlinson E.
        • Sun P.
        • Narod S.A.
        Pattern of metastatic spread in triple-negative breast cancer.
        Breast Cancer Res Treat. 2009; 115: 423-428
        • Gonzalez-Angulo A.M.
        • Timms K.M.
        • Liu S.
        • et al.
        Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
        Clin Cancer Res. 2011; 17: 1082-1089
        • Hartman A.R.
        • Kaldate R.R.
        • Sailer L.M.
        • et al.
        Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
        Cancer. 2012; 118: 2787-2795
        • Sharma P.
        • Klemp J.R.
        • Kimler B.F.
        • et al.
        Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
        Breast Cancer Res Treat. 2014; 145: 707-714
        • Wong-Brown M.S.
        • Meldrum C.J.
        • Carpenter J.E.
        • et al.
        Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
        Breast Cancer Res Treat. 2015; 150: 71-80
        • Renert G.
        • Bisland-Naggan S.
        • Barnett-Griness O.
        • et al.
        Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
        N Engl J Med. 2007; 357: 115-123
        • Goodwin P.J.
        • Phillips K.A.
        • West D.W.
        • et al.
        Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study.
        J Clin Oncol. 2012; 30: 19-26
        • Bayraktar S.
        • Gutierrez-Barrera A.M.
        • Liu D.
        • et al.
        Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
        Breast Cancer Res Treat. 2011; 130: 145-153
        • Eccles D.M.
        • Copson E.R.
        • Maishman T.
        • et al.
        Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH) [abstract].
        Cancer Res. 2017; 77 (Proceedings of the 2016 San Antonio Breast Cancer Symposium, Dec 6-10, 2016, San Antonio, TX; Philadelphia, PA: AACR) (abstract S2-S03)
        • Lee L.J.
        • Alexander B.
        • Schnitt S.J.
        • et al.
        Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
        Cancer. 2011; 117: 3093-3100
        • Tung N.
        • Gaughan E.
        • Hacker M.R.
        • et al.
        Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
        Breast Cancer Res Treat. 2014; 146: 175-182
        • Maksimenko J.
        • Irmejs A.
        • Nakazawa-Miklasevica M.
        • et al.
        Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
        Oncol Lett. 2014; 7: 278-284
        • Baretta Z.
        • Mocellin S.
        • Goldin E.
        • Olopade O.I.
        • Huo D.
        Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis.
        Medicine (Baltimore). 2016; 95: e4975
        • Byrski T.
        • Gronwald J.
        • Huzarski T.
        • et al.
        Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
        J Clin Oncol. 2010; 28: 375-379
        • Byrski T.
        • Huzarski T.
        • Dent R.
        • et al.
        Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
        Breast Cancer Res Treat. 2009; 115: 359-363
        • Silver D.P.
        • Richardson A.L.
        • Eklund A.C.
        • et al.
        Efficacy of neoadjuvant cisplatin in triple-negative breast cancer.
        J Clin Oncol. 2010; 28: 1145-1153
        • Lord C.J.
        • Ashworth A.
        BRCAness revisited.
        Nat Rev Cancer. 2016; 16: 110-120
        • Wang C.
        • Zhang J.
        • Wang Y.
        • et al.
        Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
        Ann Oncol. 2015; 26: 523-528
        • Hammond M.E.
        • Hayes D.F.
        • Dowsett M.
        • et al.
        American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
        J Clin Oncol. 2010; 28: 2784-2795
        • Hudis C.A.
        • Barlow W.E.
        • Costantino J.P.
        • et al.
        Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
        J Clin Oncol. 2007; 25: 2127-2132
        • Daly M.B.
        • Pilarski R.
        • Berry M.
        • et al.
        NCCN guidelines: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. National Comprehensive Cancer Network.
        (Available at:)
        • Kurian A.W.
        • Griffith K.A.
        • Hamilton A.S.
        • et al.
        Genetic testing and counseling among patients with newly diagnosed breast cancer.
        JAMA. 2017; 317: 531-534
        • Greenup R.
        • Buchanan A.
        • Lorizio W.
        • et al.
        Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
        Ann Surg Oncol. 2013; 20: 3254-3258
        • Atchley D.P.
        • Albarracin C.T.
        • Lopez A.
        • et al.
        Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
        J Clin Oncol. 2008; 26: 4282-4288
        • van Sprundel T.C.
        • Schmidt M.K.
        • Rookus M.A.
        • et al.
        Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
        Br J Cancer. 2005; 93: 287-292
        • Metcalfe K.
        • Gershman S.
        • Ghadirian P.
        • et al.
        Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
        BMJ. 2014; 348: g226
        • Giuliano A.E.
        • Boolbol S.
        • Degnim A.
        • et al.
        Society of surgical oncology: position statement on prophylactic mastectomy: approved by the Society of Surgical Oncology Executive Council, March 2007.
        Ann Surg Oncol. 2007; 14: 2425-2427
        • Dent R.
        • Trudeau M.
        • Pritchard K.I.
        • et al.
        Triple-negative breast cancer: clinical features and patterns of recurrence.
        Clin Cancer Res. 2007; 13: 4429-4434
        • Lin N.U.
        • Vanderplas A.
        • Hughes M.E.
        • et al.
        Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
        Cancer. 2012; 118: 5463-5472
        • Kumar P.
        • Aggarwal R.
        An overview of triple-negative breast cancer.
        Arch Gynecol Obstet. 2016; 293: 247-269
        • Ovcaricek T.
        • Frkovic S.G.
        • Matos E.
        • Mozina B.
        • Borstnar S.
        Triple negative breast cancer—prognostic factors and survival.
        Radiol Oncol. 2011; 45: 46-52
        • Rakha E.A.
        • El-Sayed M.E.
        • Green A.R.
        • Lee A.H.S.
        • Robertson J.F.
        • Ellis I.O.
        Prognostic markers in triple-negative breast cancer.
        Cancer. 2007; 109: 25-32
        • Pistelli M.
        • Pagliacci A.
        • Battelli N.
        • et al.
        Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice.
        Anticancer Res. 2013; 33: 2737-2742
        • Robson M.
        • Im S.A.
        • Senkus E.
        • et al.
        Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.
        N Engl J Med. 2017; 377: 523-533